№ files_lp_4_process_3_057958
File format: docx
Character count: 2411
File size: 21 KB
A supplement to a peer-reviewed consensus paper providing a comprehensive review and evaluation of studies on molecular profiling of mesenchymal tumors, including selection criteria, literature search methodology, and final reference selection.
Year:
2010–2025
Region / City:
Italy
Topic:
Molecular profiling of mesenchymal tumors
Document type:
Consensus paper supplement
Institution:
Italian Sarcoma Group
Audience:
Medical researchers, oncologists, pathologists
Methods:
Literature review, PubMed search, article screening
Number of articles reviewed:
2,699
Number of articles included in final analysis:
146
Additional publications considered:
December 31, 2024 – August 31, 2025
Filters applied:
Full text, clinical trials, guidelines, meta-analyses, observational studies, humans, English language
Search strategy:
Next-generation sequencing, genomic profiling, liquid biopsy, RNAseq, fusion panel, methylation
Reference list selection:
Most relevant articles according to journal guidelines
Systematic review type:
Consensus-based literature review
Screening process:
Title screening, abstract evaluation, full-text evaluation
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Protocol version:
6.0
Date:
18 September 2020
Study name:
rEECur
Study design:
International randomised controlled trial
Medical condition:
Recurrent and primary refractory Ewing sarcoma
Intervention:
Chemotherapy
Sponsor:
University of Birmingham
Sponsor protocol number:
RG_13-277
CRCTU number:
SA2015
EudraCT number:
2014-000259-99
ISRCTN reference number:
ISRCTN36453794
Chief Investigator:
Dr Martin McCabe
Coordinating institution:
Cancer Research UK Clinical Trials Unit, University of Birmingham
Geographic scope:
International
Participating regions:
United Kingdom, Germany, Italy, France, Spain, Scandinavia, Australia, New Zealand, Switzerland
Target population:
Patients with recurrent or primary refractory Ewing sarcoma
Regulatory status:
Ethics and regulatory approval required per participating country
Amendment history:
Substantial amendments between 2014 and 2016
Document type:
Clinical trial protocol
Randomisation method:
Centralised online randomisation
Trial phase:
Phase II (Germany-specific limitation noted)
Year:
2021
Region / City:
International
Topic:
Soft tissue sarcoma histopathology
Document Type:
Guide
Organization / Institution:
International Collaboration on Cancer Reporting (ICCR)
Author:
Not specified
Target Audience:
Pathologists, oncologists, medical professionals
Effective Period:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2019
Region / city:
Not specified
Theme:
Oncology
Document type:
Clinical Protocol
Authors:
Erin Rudzinski, MD; Bruce Pawel, MD; Armita Bahrami, MD; M. John Hicks, MD
Target audience:
Healthcare professionals involved in pediatric oncology
Period of validity:
Not specified
Approval date:
Not specified
Date of modifications:
February 2019
Year:
2022
Protocol Version:
4.4.0.0
Protocol Posting Date:
March 2022
Required Use Date:
December 2022
Program:
CAP Laboratory Accreditation Program
Issuing Organization:
College of American Pathologists
Committees:
CAP Cancer Committee; CAP Pathology Electronic Reporting Committees
Authors:
Uma G. Krishnamurti, MD, PhD; Barbara A. Crothers, DO
Subject:
Pathologic examination and synoptic reporting of primary uterine sarcoma resection specimens
Tumor Types Covered:
Leiomyosarcoma; Adenosarcoma; Endometrial stromal sarcoma; Undifferentiated uterine/endometrial sarcoma
Excluded Tumor Types:
Carcinoma; Lymphoma
Applicable Procedures:
Total hysterectomy; Supracervical hysterectomy; Radical hysterectomy; Salpingo-oophorectomy; Omentectomy; Peritoneal biopsy; Peritoneal washing
Reporting Standard:
Synoptic reporting format with core and conditional data elements
Staging Standards Referenced:
AJCC-UICC 8; FIGO Cancer Report 2018
Intended Users:
Pathologists and laboratories participating in CAP accreditation
Year of publication:
2025
Receipt of originals:
10/27/2025
Acceptance for publication:
11/27/2025
DOI:
https://doi.org/10.56238/isevjhv4n6-002
Authors:
Fernanda Cristina Galerani Gualtieri Parpinelli; Augustin Malzac; Henrique Lucas Codognoto; Cristina Jardelino de Lima; Guilherme Banck; Diogo Melo Mendo
Type of document:
Narrative literature review
Field:
Oncology; Orthopedic Oncology
Subject:
Multidisciplinary management of osteosarcoma, chondrosarcoma, and Ewing sarcoma
Population focus:
Pediatric and young patients with primary malignant bone tumors
Study period covered:
2015–2025
Databases consulted:
PubMed; Scopus; Cochrane
Therapeutic approaches discussed:
Surgical resection (R0 margins); Neoadjuvant and adjuvant chemotherapy (MAP; VAC/IE); Radiotherapy; Proton therapy; Immune checkpoint inhibitors; CAR-T cell therapy
Molecular aspects:
EWS-FLI1 translocation; IDH1/IDH2 mutations; Circulating tumor DNA (ctDNA)
Imaging modalities:
MRI; CT; PET-CT
Keywords:
Osteosarcoma; Chondrosarcoma; Ewing Sarcoma; Targeted Therapy; EWS-FLI1; Biomarkers; Immunotherapy
Grant Name:
ANZSA 2023 SRG
Year:
2023
Organization:
ANZSA
Related Organization:
ASSG
Document Type:
Grant Application Form
Subject Area:
Sarcoma Research
Application Components:
Applicant Details, Project Description, Budget, Lay Summary, Supporting Documents
Submission Method:
Email submission
Required Attachments:
Curriculum Vitae; Letters of Recommendation or Support (optional)
Project Duration:
12 months
Contact Email:
[email protected]
Year:
2018
Region:
North America
Subject:
Cancer data collection, Soft tissue sarcoma, GIST, Thymoma
Document type:
Guidelines and Q&A
Organization:
NAACCR, AJCC, SEER, CoC
Author:
Not specified
Target audience:
Cancer registrars, clinical coders, oncology data specialists
Effective period:
Cases diagnosed 2018 onward
Date issued:
January 11, 2018
Related resources:
ICD-O 3 Coding Guidelines, FORDS 2016, SEER 2016 Coding Manual, STORE 2018
Author:
Nik Heijmink
Student number:
6706541
Date:
12/08/2024
Type of document:
Writing assignment
Academic program:
Neuroscience and Cognition master program, Experimental and Clinical Neuroscience track
Institution:
University Medical Centre Utrecht
Department:
Department for Developmental Origins of Disease, Division Woman and Baby, Brain Center
City:
Utrecht
Country:
The Netherlands
Daily supervision:
M.J.V. Brandt, PhD
Examiner:
C.H.A. Nijboer, Associate Professor
Secondary examiner:
R.J. Pasterkamp, Full Professor
Main topic:
Hypoxic-ischemic encephalopathy and mesenchymal stem cell-derived extracellular vesicles
Key subjects:
Neuroinflammation, neurogenesis, hypothermia treatment, microglia, subventricular zone, exosomes
Year:
Not specified
Region / City:
Not specified
Topic:
Stem Cells, Regenerative Medicine
Document Type:
Product Description
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, Medical Professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Authors:
Cassandra M. Juran; Justina Zvirblyte; Yasaman Sharazi; Angela Kubik; Margareth Cheng-Campbell; Elizabeth Blaber; Eduardo Almeida
Affiliations:
Blue Marble Space Institute of Science at NASA Ames Research Center, Mountain View, CA, USA; Vilnius University, Vilnius, Lithuania; Rensselaer Polytechnic Institute, Troy, NY, USA; NASA Ames Research Center, Moffett Field, CA, USA
Research Field:
Stem cell biology; Bone regeneration; Mechanobiology; Space biology
Key Gene:
CDKN1A (Cdkn1a)
Experimental Models:
Wildtype and Cdkn1a-null mice
Methods:
Single-cell mRNA sequencing; in-vitro mechanical stretch; hindlimb unloading; running wheel and treadmill loading; spaceflight microgravity exposure
Space Mission:
Rodent Research-10 aboard the International Space Station
Duration of Spaceflight:
30 days
Biological Material:
Femur bone marrow; mesenchymal osteoprogenitors; osteoblast lineage cells
Type of Document:
Scientific research article
Institutional Context:
NASA-affiliated and academic biomedical research collaboration
Effective Date:
August 26, 2025
Product Name:
Adipose Mesenchymal Stem Cell Exosomes (ADSC-Exos)
Manufacturer:
YI MIN BIOLOGICAL MEDICINE
Contact Phone:
+86 18506213676
Company Address:
Building 1, Gangtian Industrial Park, No. 99 Gangtian Road, Industrial Park, Suzhou, Jiangsu Province, China
Product Type:
Raw material ingredient
Product Form:
Liquid form; Lyophilized powder form
Core Active Ingredient:
Exosomes secreted by adipose mesenchymal stem cells (≥1×10¹⁰ particles/mL)
Excipients:
Serum-free culture medium; Glycerol (5%-10%)
Non-Containing Components:
No antibiotics; No preservatives; No additional animal-derived materials; No heavy metals (<0.1 ppm)
Exosome Diameter:
30–150 nm (average 80–100 nm)
Marker Proteins:
CD9, CD63, CD81, CD29, CD44, CD73
Sterility:
No bacterial or fungal growth
Endotoxin Content:
<0.5 EU/mL
pH Value (Liquid Form):
6.5–7.5
Purity:
≥90%
Storage Conditions:
2–8°C or -20°C depending on form
Shelf Life:
6–24 months depending on form and temperature
Transportation Requirements:
Professional cold chain; ≤72 hours
Scope of Application:
Scientific research experiments; Cosmetics; Medical devices
Usage Restrictions:
Not for direct injection, oral administration, or direct use as drug or health supplement
Liability Statement:
Manufacturer responsible only under specified storage, transportation, and usage conditions
After-Sales Contact Email:
[email protected]
Revision Policy:
Subject to updates due to technology or regulatory changes
Year:
2026
Region / city:
Global
Subject:
Cell therapy, regenerative medicine
Document type:
Product description
Organization:
[Manufacturer / Supplier Name]
Author:
[Author / Researcher Name, if mentioned]
Target audience:
Researchers, healthcare professionals
Validity period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2021
Region / city:
Tianjin, China
Subject:
Stem Cell Therapy, Neurological Function, Ischemic Stroke, Gut Microbiota
Document type:
Research Article
Organization / Institution:
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin Key Laboratory of Translational Research of TCM Prescription and Syndrome
Author:
Zhao LN, Ma SW, Xiao J, Yang LJ, Xu SX, Zhao L
Target audience:
Researchers, Healthcare professionals, Medical practitioners
Period of validity:
Not specified
Approval date:
December 11, 2021
Date of revisions:
July 6, 2021
Publication date:
December 26, 2021
Year:
2021
Region / city:
Not specified
Topic:
Mesenchymal cells in bone marrow of AML patients
Document type:
Research Supplementary Data
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers, medical professionals
Effective period:
Not specified
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2026
Region / City:
Not specified
Topic:
Bone Regeneration, Macrophage Phenotype Switching
Document Type:
Research Article
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, Medical Professionals
Duration:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Note:
Year
Region / City:
Ottawa
Subject:
Health Insurance Coverage
Document Type:
Contractual Agreement
Organ / Institution:
Embassy of Italy
Target Audience:
Economic Operators
Period of Validity:
Five years
Year:
2024
Region / City:
Rome, Milan
Topic:
Fashion, Strategic Partnership, Business Growth
Document Type:
Press Release
Organization:
Subdued, NUO
Author:
Not specified
Target Audience:
Investors, Fashion Industry Professionals, Teenagers (14-20 years old)
Effective Period:
Not specified
Approval Date:
19 March 2024
Amendment Date:
Not specified
Name:
Tommy Lin
Date:
28 October 2020
Document type:
Student self-reflection
Educational context:
Language learning
Language studied:
Italian
Competencies addressed:
Communication, thinking, personal and social
Learning activities referenced:
Storytelling, visual presentation, scriptwriting, in-class writing, oral presentation
Assessment format:
Blog-based self-assessment
Word count referenced:
171 words
Audience:
Teacher and educational evaluators
Year:
2021
Dates:
September 15–17, 2021
Event:
XXVI Congress of the Italian Phytopathological Society (SIPaV)
Edition:
26th
Format:
Virtual congress
Organization:
Italian Phytopathological Society (SIPaV)
Committees:
Scientific Committee; Organizing Committee
Document type:
Second announcement and scientific programme
Main topics:
Plant-pathogen interactions; Plant pathogens and the microbial world; Innovative approaches to plant disease control
Key activities:
Opening Lecture; Oral Communications; Poster Sessions; SIPaV Awards “Giovanni Scaramuzzi” 2020 and 2021; Best Poster Awards; General Assembly of SIPaV Members
Abstract submission deadline:
June 30th, 2021
Notification of acceptance:
by July 23rd, 2021
Publication outlet:
Journal of Plant Pathology (JPP)
Language of abstracts:
English
Submission method:
E-mail attachment in Word format (.doc or .docx)
Year:
2017
Region / City:
Chicago
Subject:
Italian-American culture, Jazz, African American influence
Document Type:
Book
Institution:
University of Chicago Press
Author:
John Gennari
Target Audience:
Scholars of American and Italian-American culture, music enthusiasts
Period of validity:
N/A
Approval Date:
N/A
Date of changes:
N/A